How to Use Buprenorphine to Treat Dyspnea

Refractory dyspnea is a prevalent and distressing symptom among patients with serious illness, significantly impacting quality of life. While full μ-opioid agonists are commonly used to alleviate dyspnea—and are often effective—their use may be limited by side effects such as sedation, nausea, or constipation, which can compromise efficacy and tolerability. Buprenorphine, a partial μ-receptor agonist and κ-receptor antagonist, represents a promising yet underutilized option for managing dyspnea in this population.

In this Interprofessional Grand Rounds session, Drs. Diane Meier and Calvin Gross will explore evidence-based approaches to assessing and treating dyspnea with buprenorphine. They will review the current literature, discuss insights from clinical experience, and identify key areas for future research. The session will highlight the unique pharmacological properties of buprenorphine, including its efficacy in relieving dyspnea, its lower risk of adverse effects compared to full μ-opioids, and its improved safety profile in patients with serious illnesses.

Attendees will gain a deeper understanding of the critical role of dyspnea management in optimizing patient-centered care. Emphasis will be placed on tailoring interventions to meet individual patient needs, with a focus on improving comfort, functionality, and overall quality of life. This session aims to equip clinicians with practical strategies and foster greater awareness of buprenorphine as a valuable tool in the palliative care arsenal.